CIP, Cancer Immunology Project

♨️Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy

✅New Paper by CIP

🌀Cancer immunotherapy especially immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers.

🌀Blockade of programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects for many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability.

🌀In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy, adverse events associated with PD-1/L1/2 inhibitors and the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.

Source: https://doi.org/10.1155/2021/6661406

@cip_usern
@usern_net

www.tgoop.com/CIP_USERN/298

287 viewsedited  Feb 28, 2021 at 12:28

♨️Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy

✅New Paper by CIP

🌀Cancer immunotherapy especially immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers.

🌀Blockade of programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects for many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability.

🌀In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy, adverse events associated with PD-1/L1/2 inhibitors and the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.

Source: https://doi.org/10.1155/2021/6661406

@cip_usern
@usern_net

BY CIP, Cancer Immunology Project